HOUSE_OVERSIGHT_025889.jpg

Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class,” Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called “bad cholesterol”, by as much as 60%, far more than the statin drugs alone. It is the first drug to work by targeting a protein called PCSK9. Mutations in the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition that causes high cholesterol, and for people who have heart disease, like those who’ve had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies will get a significant discount, because Amgen and Regeneron will compete by giving the insurers rebates. Recommended by Forbes Most Popular Photos: America's New Manufacturing Boomtowns oe Eeaee? Most Popular Barrel Rolling With A Thrillionaire Entrepreneur Most Popular Photos: The 10 Best And Worst States To Make A Living In 2015 Trending on LinkedIn Donald Trump And The Decline Of American Character--A Cautionary Tale Most Popular Photos: America's New Manufacturing Boomtowns Most Popular Barrel Rolling With A Thrillionaire Entrepreneur Most Popular Photos: The 10 Best And Worst States To Make A Living In 2015 HOUSE_OVERSIGHT_025889